Background
Background Maintenance of Maintenance of treatment effect is important for the treatment effect is important for the choice of treatment for social phobia. choice of treatment for social phobia.
Aims Aims To examine the effect of exposure
To examine the effect of exposure therapy and sertraline 28 weeks after therapy and sertraline 28 weeks after cessation of medical treatment. cessation of medical treatment.
Method Method In this study 375 patients with
In this study 375 patients with social phobia were randomised to social phobia were randomised to treatment with sertraline or placebo for treatment with sertraline or placebo for 24 weeks, with or withoutthe addition of 24 weeks, with or withoutthe addition of exposure therapy.Fifty-two weeks after exposure therapy.Fifty-two weeks after inclusion, 328 patients were evaluated by inclusion, 328 patients were evaluated by the same psychometric tests as at baseline the same psychometric tests as at baseline and the end of treatment (24 weeks). and the end of treatment (24 weeks).
Results
Results The exposure therapy group
The exposure therapy group and the placebo group had a further and the placebo group had a further improvement in scores on social phobia improvement in scores on social phobia during follow-up: mean change in the during follow-up: mean change in the Clinical Global Impression^Social Clinical Global Impression^Social Phobia overall severity score was Phobia overall severity score was 0.45 (95% CI 0.16^0.65, 0.45 (95% CI 0.16^0.65, P P5 50.01) 0.01) for the exposure group, and 0.25 for the exposure group, and 0.25 (95% CI 0.00^0.48, (95% CI 0.00^0.48, P P5 50.05) for the 0.05) for the placebo group. At week 52 the sertraline placebo group. At week 52 the sertraline plus exposure group and the sertraline-plus exposure group and the sertralinealone group had a significant deterioration alone group had a significant deterioration onthe 36 -item Short Form Health Survey onthe 36 -item Short Form Health Survey compared with exposure alone. compared with exposure alone.
Conclusions Conclusions Exposure therapy alone
Exposure therapy alone yielded a further improvement during yielded a further improvement during follow-up, whereas exposure therapy follow-up, whereas exposure therapy combined with sertraline and sertraline combined with sertraline and sertraline alone showed a tendency towards alone showed a tendency towards deterioration after the completion of deterioration after the completion of treatment. treatment.
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The short-term effect of treatment of social The short-term effect of treatment of social phobia has been demonstrated in several phobia has been demonstrated in several studies, and both cognitive-behavioural studies, and both cognitive-behavioural treatments and pharmacological inter-treatments and pharmacological interventions have given positive findings ventions have given positive findings (Mattick (Mattick et al et al, 1989; Gelernter , 1989; Gelernter et al et al, , 1991; Liebowitz 1991; Liebowitz et al et al, 1992; Versiani , 1992; Versiani et et al al, 1992; Davidson , 1992; Davidson et al et al, 1993; Heimberg , 1993; Heimberg et al et al, 1993; Van Vlet , 1993; Van Vlet et al et al, 1994; Katzelnick , 1994; Katzelnick et al et al, 1995; Taylor, 1996; Stein , 1995; Taylor, 1996; Stein et al et al, 1998 Stein et al et al, ). , 1998 . The studies vary widely in terms of out-The studies vary widely in terms of outcome measures, type of control groups, come measures, type of control groups, sample selections and whether treatment is sample selections and whether treatment is offered individually or in groups, making offered individually or in groups, making it impossible to draw meaningful compari-it impossible to draw meaningful comparisons between studies. A few studies have sons between studies. A few studies have compared the effect of psychological treat-compared the effect of psychological treatment with the effect of medication (Turner ment with the effect of medication (Turner et al et al, 1994; Heimberg , 1994; Heimberg et al et al, 1998) , but it , 1998), but it has been difficult to identify treatments that has been difficult to identify treatments that are clearly superior to others. Which form are clearly superior to others. Which form of treatment is chosen will therefore mainly of treatment is chosen will therefore mainly depend on the patient's preferences and the depend on the patient's preferences and the availability of services. However, the main-availability of services. However, the maintenance of treatment effects after cessation tenance of treatment effects after cessation of active treatment is also important in this of active treatment is also important in this decision. decision.
In this study we examine the effect on In this study we examine the effect on generalised social phobia of 24 weeks of generalised social phobia of 24 weeks of treatment with sertraline, with or without treatment with sertraline, with or without the addition of exposure therapy, 1 year the addition of exposure therapy, 1 year after the start of treatment. after the start of treatment.
METHOD METHOD
People aged 18-65 years with generalised People aged 18-65 years with generalised social phobia according to DSM-IV criteria social phobia according to DSM-IV criteria (American Psychiatric Association, 1994) (American Psychiatric Association, 1994) of at least 1 year's duration and rated of at least 1 year's duration and rated as moderately ill (a score of at least 4) on as moderately ill (a score of at least 4) on the the overall severity item of the severity overall severity item of the severity sub-scale of the Clinical Global Impression sub-scale of the Clinical Global Impression -Social Phobia -Social Phobia scale (CGI-SP, range 1-7, scale (CGI-SP, range 1-7, Davidson Davidson et et al al, 1993) were eligible for in-, 1993) were eligible for inclusion in clusion in the study. Participants were con-the study. Participants were consecutively secutively recruited from people seeking recruited from people seeking medical medical care at 41 different primary care care at 41 different primary care centres in Norway and Sweden ( centres in Norway and Sweden (n n¼289) 289) and from advertisements in newspapers and from advertisements in newspapers and other media ( and other media (n n¼159). Three hundred 159). Three hundred and seventy-five patients were randomly and seventy-five patients were randomly assigned by a computer to receive double-assigned by a computer to receive doubleblind sertraline or placebo in blocks of blind sertraline or placebo in blocks of eight, so that four patients in each block eight, so that four patients in each block were randomised to each treatment. No were randomised to each treatment. No other stratification factor was used. Each other stratification factor was used. Each block was assigned to a specific general block was assigned to a specific general practitioner. In both the sertraline and the practitioner. In both the sertraline and the placebo groups half of the patients were placebo groups half of the patients were randomly allocated to exposure therapy or randomly allocated to exposure therapy or to general medical care only. A separate to general medical care only. A separate randomisation list was made for exposure randomisation list was made for exposure or non-exposure treatment. Sealed envel-or non-exposure treatment. Sealed envelopes for allocations from this list were kept opes for allocations from this list were kept by the investigators and opened after in-by the investigators and opened after inclusion of the patient into the study. During clusion of the patient into the study. During this procedure equal numbers of partici-this procedure equal numbers of participants were assigned to each treatment pants were assigned to each treatment option in each block. Tablets were pack-option in each block. Tablets were packaged and numbered by the sponsor and aged and numbered by the sponsor and personally delivered to each investigator. personally delivered to each investigator. Participants were evaluated at week 24 Participants were evaluated at week 24 (post-treatment, (post-treatment, n n¼346) and at week 52 346) and at week 52 (follow-up, (follow-up, n n¼328; Fig. 1 ). Of the original 328; Fig. 1 .1) years and the 9.1) years and the mean duration of illness was 23.6 (s.d. mean duration of illness was 23.6 (s.d.¼ 12.2) years. Patients with comorbid dys-12.2) years. Patients with comorbid dysthymia or specific phobias were allowed thymia or specific phobias were allowed to enter the study; those with panic disorder to enter the study; those with panic disorder with onset before social phobia or any with onset before social phobia or any other current anxiety or major depressive other current anxiety or major depressive disorder, substance misuse or an eating dis-disorder, substance misuse or an eating disorder were not eligible. In addition, pa-order were not eligible. In addition, patients with a lifetime history of bipolar tients with a lifetime history of bipolar disorder or psychosis were excluded. A co-disorder or psychosis were excluded. A comorbid psychiatric disorder was diagnosed morbid psychiatric disorder was diagnosed in 133 (35%) patients; 101 (27%) had in 133 (35%) patients; 101 (27%) had phobic anxiety disorder, 6 (1.6%) panic phobic anxiety disorder, 6 (1.6%) panic disorder, 6 (1.6%) dysthymia and 20 disorder, 6 (1.6%) dysthymia and 20 (5.3%) other diagnoses. (5.3%) other diagnoses.
All patients were scheduled for nine All patients were scheduled for nine meetings with the investigator during the meetings with the investigator during the first 16 weeks of treatment and a final first 16 weeks of treatment and a final efficacy assessment after 24 weeks. The efficacy assessment after 24 weeks. The patients were randomised to four treatment patients were randomised to four treatment groups and treated by general practitioners groups and treated by general practitioners for 24 weeks with sertraline or a pill for 24 weeks with sertraline or a pill placebo, combined with 12 weeks of expo-placebo, combined with 12 weeks of exposure therapy or of only general medical sure therapy or of only general medical care. Exposure therapy was given in eight care. Exposure therapy was given in eight sessions for the first 12 weeks of treatment. sessions for the first 12 weeks of treatment. Each of the sessions had an estimated dura-Each of the sessions had an estimated duration of 15-20 min. In the first sessions, tion of 15-20 min. In the first sessions, main problem areas were identified and main problem areas were identified and agreement was reached about homework agreement was reached about homework assignments. In the remaining sessions, the assignments. In the remaining sessions, the patients were instructed to gradually patients were instructed to gradually expose themselves to feared situations, expose themselves to feared situations, and to keep exposure homework diaries. and to keep exposure homework diaries. Details of the exposure therapy have been Details of the exposure therapy have been published elsewhere (Haug published elsewhere (Haug et al et al, 2000) . , 2000) . At week 24, patients treated with sertraline At week 24, patients treated with sertraline were significantly more improved than were significantly more improved than those who did not receive sertraline those who did not receive sertraline ( (w w 2 2 ¼12.53, 12.53, P P5 50.001; OR 0.001; OR¼0.534, 95% 0.534, 95% CI 0.347-0.835). No significant difference CI 0.347-0.835). No significant difference was observed between those who received was observed between those who received exposure therapy and those who did not exposure therapy and those who did not ( (w w 2 2 ¼2.18, 2.18, P P¼0.140; OR 0.140; OR¼0.732, 95% 0.732, 95% CI 0.475-1.134). In the pairwise compari-CI 0.475-1.134). In the pairwise comparisons, combined sertraline and exposure sons, combined sertraline and exposure ( (w w 2 2 ¼12.32, 12.32, P P5 50.001) and sertraline alone 0.001) and sertraline alone ( (w w 2 2 ¼10.13, 10.13, P P¼0.002) were significantly 0.002) were significantly superior to placebo. Trends towards superior to placebo. Trends towards increased efficacy of exposure alone increased efficacy of exposure alone compared with placebo ( compared with placebo (P P¼0.083) and 0.083) and combined sertraline and exposure combined sertraline and exposure compared with exposure alone ( compared with exposure alone (P P¼0.059) 0.059) were also observed. More-detailed results were also observed. More-detailed results have been presented in an earlier paper have been presented in an earlier paper (Blomhoff (Blomhoff et al et al, 2001) . One year after , 2001). One year after inclusion, all patients were asked to inclusion, all patients were asked to participate in a follow-up assessment (week participate in a follow-up assessment (week 52). Those who had not improved satisfac-52). Those who had not improved satisfactorily at the end of week 24 could be torily at the end of week 24 could be offered further treatment during the offered further treatment during the follow-up period -either psychological follow-up period -either psychological treatment or medication, as decided by the treatment or medication, as decided by the clinical judgement of the general practi-clinical judgement of the general practitioner. At week 52 the participants tioner. At week 52 the participants attended an interview and filled in the same attended an interview and filled in the same questionnaires used for assessment at base-questionnaires used for assessment at baseline and at the completion of therapy (24 line and at the completion of therapy (24 weeks). weeks).
Instruments Instruments
The Mini International Neuropsychiatric The Mini International Neuropsychiatric Interview (MINI-R; Sheehan Interview (MINI-R; Sheehan et al et al, 1994) , 1994) was used to assess DSM-IV psychiatric was used to assess DSM-IV psychiatric diagnoses. The Clinical Global Impression diagnoses. The Clinical Global Impression Severity Scale (CGI-SP; Liebowitz, 1992) Severity Scale (CGI-SP; Liebowitz, 1992) 
Statistical procedures Statistical procedures
The program SAS version 6.12 for Win-The program SAS version 6.12 for Windows (SAS Institute, 1997) was employed dows (SAS Institute, 1997) was employed in all analyses. All efficacy analyses were in all analyses. All efficacy analyses were on the intention-to-treat patient popu-on the intention-to-treat patient population: this population was defined as those lation: this population was defined as those who received at least one dose of medi-who received at least one dose of medication and at least one efficacy evaluation cation and at least one efficacy evaluation post-baseline. All statistical tests were post-baseline. All statistical tests were two-tailed with two-tailed with a a¼0.05. Sample size 0.05. Sample size calculation was based on an estimated calculation was based on an estimated 20% difference between active drug and 20% difference between active drug and placebo. This required a sample size of at placebo. This required a sample size of at least 340 patients to detect a significant least 340 patients to detect a significant difference if difference if b b¼0.10 and the drop-out rate 0.10 and the drop-out rate is 35%. This procedure made the study is 35%. This procedure made the study primarily powered for analyses of sertraline primarily powered for analyses of sertraline v v. non-sertraline and exposure . non-sertraline and exposure v. v. non-nonexposure, but allowed also pairwise com-exposure, but allowed also pairwise comparisons between the treatment groups. In parisons between the treatment groups. In the latter analyses, however, the power the latter analyses, however, the power was reduced and the risk of false-negative was reduced and the risk of false-negative results increased. Repeated-measures analy-results increased. Repeated-measures analysis of covariance for each scale measure-sis of covariance for each scale measurement at 24 weeks and 52 weeks was done ment at 24 weeks and 52 weeks was done to test differences between treatment to test differences between treatment groups globally, adjusted for baseline groups globally, adjusted for baseline values at week 0. Multiple ordinal logistic values at week 0. Multiple ordinal logistic 313 313 regression was also used to identify any regression was also used to identify any statistical interaction between treatment statistical interaction between treatment groups on response. Pairwise comparisons groups on response. Pairwise comparisons for changes from week 24 to week 52, for changes from week 24 to week 52, adjusted for baseline, were made between adjusted for baseline, were made between each of the three active-treatment groups each of the three active-treatment groups and the placebo-only group. At each and the placebo-only group. At each time point (24 weeks and 52 weeks) in the time point (24 weeks and 52 weeks) in the time point analyses all groups were com-time point analyses all groups were compared pairwise, with Bonferroni pared pairwise, with Bonferroni P P-value -value adjustments for each scale analysed. adjustments for each scale analysed.
RESULTS

Of the 375 patients assessed at baseline, Of the 375 patients assessed at baseline, 346 had a post-therapy assessment at week 346 had a post-therapy assessment at week 24, and 328 a follow-up assessment at week 24, and 328 a follow-up assessment at week 52. Only 18 patients were lost to follow-up 52. Only 18 patients were lost to follow-up between week 24 and week 52. The main between week 24 and week 52. The main reasons for patients dropping out were the reasons for patients dropping out were the lack of perceived need for further treat-lack of perceived need for further treatment, events unrelated to treatment such ment, events unrelated to treatment such as moving to another area, or unknown as moving to another area, or unknown reasons ( Fig. 1 ). reasons ( Fig. 1 ).
Changes in psychometric scores
Changes in psychometric scores from baseline to week 52 from baseline to week 52 All four study groups had a significant All four study groups had a significant reduction in scores on CGI-SP (all sub-reduction in scores on CGI-SP (all subscales), SPS, Brief Social Phobia Scale (all scales), SPS, Brief Social Phobia Scale (all sub-scales; Davidson sub-scales; Davidson et al et al, 1991) , MFQ , 1991), MFQ and FNE ( and FNE (P P5 50.001) from baseline to week 0.001) from baseline to week 52. There were also significant reductions 52. There were also significant reductions in MADRS score and in scores on the SDI in MADRS score and in scores on the SDI and SF-36. and SF-36.
Changes in psychometric scores from week 24 to week 52 from week 24 to week 52
Participants who had been treated with ex-Participants who had been treated with exposure alone had a significant improvement posure alone had a significant improvement in scores on the CGI-SP overall severity in scores on the CGI-SP overall severity sub-scale (mean change 0.45, 95% CI sub-scale (mean change 0.45, 95% CI 0.16-0.65, 0.16-0.65, P P5 50.01) and disability sub-0.01) and disability subscale (mean change 0.32, 95% CI 0.06-scale (mean change 0.32, 95% CI 0.06-0.52, 0.52, P P5 50.01), and on the SPS (mean 0.01), and on the SPS (mean change 3.86, 95% CI 1.27-5.64, change 3.86, 95% CI 1.27-5.64, P P5 50.01) 0.01) during follow-up. The placebo-only group during follow-up. The placebo-only group also had a significant improvement on also had a significant improvement on the CGI-SP overall severity sub-scale the CGI-SP overall severity sub-scale (mean change 0.25, 95% CI 0.00-0.48, (mean change 0.25, 95% CI 0.00-0.48, P P5 50.05), disability sub-scale (mean change 0.05), disability sub-scale (mean change 0.32, 95% CI 0.08-0.53, 0.32, 95% CI 0.08-0.53, P P5 50.01) and 0.01) and performance sub-scales (mean change performance sub-scales (mean change 0.36, 95% CI 0.05-0.56, 0.36, 95% CI 0.05-0.56, P P5 50.05). For 0.05). For the sertraline plus exposure and the the sertraline plus exposure and the sertraline-alone groups there was a slight sertraline-alone groups there was a slight deterioration in scores on most of the CGI deterioration in scores on most of the CGI sub-scales and on SPS, but the changes were sub-scales and on SPS, but the changes were not significant ( . Changes in sertraline plus exposure compared with sertraline plus exposure compared with sertraline alone and in exposure alone com-sertraline alone and in exposure alone compared with placebo were non-significant pared with placebo were non-significant (Tables 3 and 4 , Figs 3 and 4) . (Tables 3 and 4 , Figs 3 and 4) .
The sertraline plus exposure group had The sertraline plus exposure group had a significant deterioration in MADRS score a significant deterioration in MADRS score ( (P P5 50.01) between week 24 and week 52. 0.01) between week 24 and week 52. The changes in the other treatment groups The changes in the other treatment groups were not significant. were not significant.
Treatment during the follow-up Treatment during the follow-up period period
Sixty-six patients (20.5%) were treated Sixty-six patients (20.5%) were treated with selective serotonin reuptake inhibitors with selective serotonin reuptake inhibitors (SSRIs): 13 (15.5%) in the combined sertra-(SSRIs): 13 (15.5%) in the combined sertraline plus exposure group, 18 (21.6%) in line plus exposure group, 18 (21.6%) in the sertraline-alone group, 14 (19.2%) in the sertraline-alone group, 14 (19.2%) in the exposure group and 21 (19.5%) in the the exposure group and 21 (19.5%) in the placebo group. Twenty-seven patients placebo group. Twenty-seven patients (7.6%) were offered exposure therapy by (7.6%) were offered exposure therapy by their general practitioner during the their general practitioner during the follow-up period, and 26 patients (7.0%) follow-up period, and 26 patients (7.0%) had been referred to a psychologist or had been referred to a psychologist or psychiatrist. psychiatrist.
Psychiatric diagnoses at week 52 Psychiatric diagnoses at week 52
A total of 19 patients (5.7%) had a major A total of 19 patients (5.7%) had a major depression according to DSM-IV at week depression according to DSM-IV at week 52. Ten of these patients were in the group 52. Ten of these patients were in the group who had received the combined sertraline who had received the combined sertraline and exposure therapy, 2 had received and exposure therapy, 2 had received sertraline alone, 4 had received exposure sertraline alone, 4 had received exposure alone and 3 were in the placebo group. alone and 3 were in the placebo group.
Employment records Employment records
At the week 52 assessment 223 patients At the week 52 assessment 223 patients were employed and 33 were students. were employed and 33 were students. About a third (32%) of the patients were About a third (32%) of the patients were on sick leave the year preceding baseline; on sick leave the year preceding baseline; less than a quarter (23%) were on sick less than a quarter (23%) were on sick leave the year preceding follow-up. There leave the year preceding follow-up. There was also a slight reduction in mean days was also a slight reduction in mean days of sick leave: 15.8 days in the year preced-of sick leave: 15.8 days in the year preceding baseline and 13.0 days in the year ing baseline and 13.0 days in the year preceding follow-up. preceding follow-up.
DISCUSSION DISCUSSION
This is, to our knowledge, the largest This is, to our knowledge, the largest follow-up study of the treatment of social follow-up study of the treatment of social phobia, covering 375 patients. The study phobia, covering 375 patients. The study was carried out in primary care by a total was carried out in primary care by a total of 45 physicians treating about 8 patients of 45 physicians treating about 8 patients each. The patients were well known to the each. The patients were well known to the doctors and this provided an opportunity doctors and this provided an opportunity to make follow-up assessments of nearly to make follow-up assessments of nearly all patients. Only 18 patients were lost to all patients. Only 18 patients were lost to follow-up between weeks 24 and 52. follow-up between weeks 24 and 52.
Maintenance of treatment effect Maintenance of treatment effect
All four treatment groups had a significant All four treatment groups had a significant improvement from baseline to week 52 on improvement from baseline to week 52 on all the psychometric assessments. Patients all the psychometric assessments. Patients who had been given exposure therapy or who had been given exposure therapy or placebo had a further improvement in placebo had a further improvement in 31 5 31 5 social phobia after the end of the treatment social phobia after the end of the treatment period, whereas patients who had been period, whereas patients who had been treated with sertraline -either alone or in treated with sertraline -either alone or in combination with exposure therapy -had combination with exposure therapy -had no further improvement during the fol-no further improvement during the follow-up period and there was a tendency low-up period and there was a tendency towards deterioration. However, the towards deterioration. However, the deterioration was significant only for the deterioration was significant only for the score on SF-36 (Table 2) . At week 52 the score on SF-36 (Table 2) . At week 52 the participants in both the sertraline-alone participants in both the sertraline-alone and the combined sertraline plus exposure and the combined sertraline plus exposure groups had a significant deterioration com-groups had a significant deterioration compared with patients in the exposure-alone pared with patients in the exposure-alone and placebo groups. These results are in and placebo groups. These results are in accordance with the study by Liebowitz accordance with the study by Liebowitz et et al al (1999) , who concluded that cognitive- (1999) , who concluded that cognitivebehavioural group therapy and phenelzine behavioural group therapy and phenelzine differed in their long-term effects, with a differed in their long-term effects, with a more favourable outcome for the group more favourable outcome for the group therapy. They also accord with the findings therapy. They also accord with the findings by Marks by Marks et al et al (1993) , in a multi-centre (1993), in a multi-centre study of alprazolam and exposure therapy study of alprazolam and exposure therapy in panic disorder, that gains after alprazo-in panic disorder, that gains after alprazolam were lost during follow-up, whereas lam were lost during follow-up, whereas gains after exposure were maintained. gains after exposure were maintained. Combining alprazolam with exposure mar-Combining alprazolam with exposure marginally enhanced gains during treatment, ginally enhanced gains during treatment, but impaired improvement thereafter. Bar-but impaired improvement thereafter. Barlow low et al et al (2000), in a study of imipramine (2000), in a study of imipramine and cognitive-behavioural therapy in the and cognitive-behavioural therapy in the treatment of panic, reported similar results. treatment of panic, reported similar results. From this we can conclude that exposure From this we can conclude that exposure techniques applied in situations with low techniques applied in situations with low levels of anxiety achieved by medication levels of anxiety achieved by medication may have less impact than exposure may have less impact than exposure therapy applied in situations with a higher therapy applied in situations with a higher level of anxiety, and may lead to a higher level of anxiety, and may lead to a higher degree of relapse after end of treatment. degree of relapse after end of treatment. During the follow-up period about a fifth During the follow-up period about a fifth of the patients were treated with SSRIs, of the patients were treated with SSRIs, 25 (7.5%) were given exposure therapy by 25 (7.5%) were given exposure therapy by their general practitioner and 23 (7.0%) their general practitioner and 23 (7.0%) were referred to psychiatrists or psycholo-were referred to psychiatrists or psychologists. The treatment was initiated at the dis-gists. The treatment was initiated at the discretion of the general practitioners, so we cretion of the general practitioners, so we lack information about whether the treat-lack information about whether the treatment was given because of insufficient ment was given because of insufficient improvement at week 24 or because of re-improvement at week 24 or because of relapse. However, this additional treatment lapse. However, this additional treatment might have contributed to the maintenance might have contributed to the maintenance of treatment effect during the follow-up of treatment effect during the follow-up period. period.
General effects General effects
A substantial proportion of the patients im-A substantial proportion of the patients improved regardless of the treatment given, proved regardless of the treatment given, and even in the placebo-alone group only and even in the placebo-alone group only about a fifth of the patients were in need about a fifth of the patients were in need of additional treatment during the follow-of additional treatment during the followup period. The fact that social phobia was up period. The fact that social phobia was focused on as a problem, combined with focused on as a problem, combined with regular contact with a general practitioner regular contact with a general practitioner in a total of 11 sessions over 24 weeks, in a total of 11 sessions over 24 weeks, seemed to be sufficient treatment for many seemed to be sufficient treatment for many patients. patients.
Methodological considerations Methodological considerations
The general practitioners evaluated their The general practitioners evaluated their own patients at both week 24 and week own patients at both week 24 and week 52. This lack of masking may represent a 52. This lack of masking may represent a potential bias. Since many of these doctors potential bias. Since many of these doctors worked in single-handed practices, it was worked in single-handed practices, it was difficult to obtain masked efficacy difficult to obtain masked efficacy measures. However, scores on social measures. However, scores on social phobia were achieved both on investigator-phobia were achieved both on investigatorrated CGI-SP overall severity and on rated CGI-SP overall severity and on patient-rated SPS. patient-rated SPS.
To evaluate the specific effects of expo-To evaluate the specific effects of exposure therapy and sertraline, a waiting-list sure therapy and sertraline, a waiting-list control group could have been useful. In control group could have been useful. In addition, this study does not inform us of addition, this study does not inform us of follow-up periods longer than 28 weeks. follow-up periods longer than 28 weeks. There was no systematic registration of re-There was no systematic registration of relapses during follow-up and the physicians lapses during follow-up and the physicians initiated additional treatment based on initiated additional treatment based on their own clinical judgement. This limits their own clinical judgement. This limits our possibility to draw firm conclusions our possibility to draw firm conclusions about maintenance therapy and relapse pre-about maintenance therapy and relapse prevention. However, the study was naturalis-vention. However, the study was naturalistic and was conducted in general practice, tic and was conducted in general practice, where most patients with social phobia will where most patients with social phobia will have their treatment. The study also had a have their treatment. The study also had a large sample size, which strengthens the large sample size, which strengthens the statistical power. statistical power.
Which treatment should be chosen Which treatment should be chosen for social phobia? for social phobia?
Exposure therapy, sertraline and the combi-Exposure therapy, sertraline and the combination of sertraline and exposure therapy nation of sertraline and exposure therapy are all effective treatments for social are all effective treatments for social phobia. Sertraline and the combination of phobia. Sertraline and the combination of sertraline and exposure seemed to have a sertraline and exposure seemed to have a short-term advantage, but gains were short-term advantage, but gains were reduced during follow-up. For exposure reduced during follow-up. For exposure therapy alone there seemed to be a further therapy alone there seemed to be a further improvement after the end of active treat-improvement after the end of active treatment, and there are indications that expo-ment, and there are indications that exposure therapy alone is more effective in the sure therapy alone is more effective in the long term than exposure in combination long term than exposure in combination with sertraline treatment. For some with sertraline treatment. For some 317 317
CLINICAL IMPLICATIONS CLINICAL IMPLICATIONS
& & Sertraline, exposure therapy, and combined treatment with sertraline and Sertraline, exposure therapy, and combined treatment with sertraline and exposure therapy are all effective treatments for social phobia. exposure therapy are all effective treatments for social phobia.
& & Treatment with exposure therapy alone seems to give further improvement Treatment with exposure therapy alone seems to give further improvement subsequently, whereas patients treated with sertraline show a tendency towards subsequently, whereas patients treated with sertraline show a tendency towards deterioration after cessation of medication. deterioration after cessation of medication.
& & Exposure therapy given alone is more effective in the long term than when given in Exposure therapy given alone is more effective in the long term than when given in combination with sertraline. combination with sertraline.
LIMITATIONS LIMITATIONS
& & The general practitioners evaluated their own patients at both week 24 and week
The general practitioners evaluated their own patients at both week 24 and week 52.
52.
& & There was no waiting-list control group in the study.
There was no waiting-list control group in the study. 
Prediction of treatment outcome in social phobia: a Prediction of treatment outcome in social phobia: a cross validation. cross validation. Behaviour Research and Therapy Behaviour Research and Therapy, , 37 37, , 659^670. 659^670.
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